Loading... Please wait... Loading... Please wait...
ESTIMATED
04/16/2020
04/16/2020
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | -$2.14 | -$2.14 | -$2.14 |
Altamira Therapeutics Ltd. last posted its earnings results on Thursday, April 16th, 2020. The company reported $-119.25205 earnings per share for the quarter, missing analysts' consensus estimates of $-32 by $87.25205. The company had revenue of 52,735 for the quarter and had revenue of 0 for the year. Altamira Therapeutics Ltd. has generated $-15 earnings per share over the last year ($-14.8 diluted earnings per share) and currently has a price-to-earnings ratio of -0.04. Altamira Therapeutics Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 10th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 06/28/2023 | Q2 2023 | -$12.91 | $52,735 | 03/30/2023 | Q1 2023 | -$12.91 | $52,735 | 05/16/2023 | Q4 2022 | -$2.89 | $0 | 09/29/2022 | Q3 2022 | -$199.86 | $-458,691 | 11/30/2022 | Q2 2022 | -$106.32 | $56.58 M | $145,399 | 03/30/2022 | Q1 2022 | -$106.32 | $145,399 | 04/12/2022 | Q4 2021 | $164.89 | $0 | 09/29/2021 | Q3 2021 | -$149.92 | $0 | 06/29/2021 | Q2 2021 | -$108.47 | $0 | 03/31/2021 | Q1 2021 | -$108.47 | $0 | 03/31/2021 | Q4 2020 | -$148.91 | $237,000 | 09/29/2020 | Q3 2020 | -$148.91 | $0 | 09/17/2020 | Q2 2020 | -$115.96 | $0 | 03/30/2020 | Q1 2020 | -$115.96 | $0 | 04/16/2020 | Q4 2019 | -$32.00 | -$83.44 | -51.44 | $-56,000 | 09/29/2019 | Q3 2019 | $0.00 | $0 | 06/30/2019 | Q2 2019 | -$165.84 | $0 | 03/30/2019 | Q1 2019 | $0.00 | $0 | 03/14/2019 | Q4 2018 | -$485.21 | $1.27 M | 09/30/2018 | Q3 2018 | -$569.22 | $0 |
|---|
A. Altamira Therapeutics Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 10th, 2024 based off last year's report dates.
A. The conference call for Altamira Therapeutics Ltd.'s latest earnings report can be listened to online.
A. The conference call transcript for Altamira Therapeutics Ltd.'s latest earnings report can be read online.
A. Altamira Therapeutics Ltd. (NASDAQ:CYTO) has a recorded net income of $0. Altamira Therapeutics Ltd. has generated $-14.8 earnings per share over the last four quarters.
A. Altamira Therapeutics Ltd. (NASDAQ:CYTO) has a price-to-earnings ratio of -0.04 and price/earnings-to-growth ratio is -0.
